Anteris Technologies has 3D single-piece Transcatheter Heart Valve DurAVR™ featured during TVT 2021

Anteris Technologies Ltd (ASX:AVR, OTCQB:AMEUF, FRA:DDF) has had its unique 3D single-piece Transcatheter Heart Valve DurAVR™ featured in the innovation section of the Transcatheter Valve Therapies Structural Heart Summit (TVT 2021). DurAVR™ was also recognised by the founder and chairman emeritus of the Cardiovascular Research Foundation (CRF), which sponsors TVT 2021. The selection process for the innovation award was highly competitive, drawing submissions from large and small companies alike in the TAVR, mitral, tricuspid and LAA closure (Left Atrial Appendage) spaces. Unlocks clinical and anatomical challenges Anteris chief executive officer Wayne Paterson said: “The DurAVR™ THV System unlocks the clinical and anatomical challenges that patients are still burdened with in today’s commercially available TAVR devices. “DurAVR™ is the beginning of a new era in the next generation of TAVR devices that will last the life of a patient – a critical need in these younger and more active patients. “Having DurAVR™ recognized at this very important meeting is a clear demonstration of support for our potential within the Structural Heart Faculty.” Structural Heart Summit This year’s TVT Structural Heart Summit was the first in-person meeting post-COVID-19 restrictions, where Anteris took the opportunity to meet the members of its Medical Advisory Board to demonstrate progress on the DurAVR™ THV and ComASUR™ transfemoral delivery system development program. The company also discussed ongoing preparation for submission to the US FDA later this year for an early feasibility study. Interventional cardiologist at the Minneapolis Heart Institute at the Abbott Northwestern Hospital, Dr Paul Sorajja MD made the innovation presentation during TVT 2021. Dr Sorajja highlighted the benefits the DurAVR™ THV System brings to patients and heart teams around the world in providing them with an Aortic Valve Replacement that lasts longer and works better than currently available devices. ‘Top picks’ for innovations Besides the innovation presentation, Columbia University’s Professor of Cardiology and director of the Center for Interventional Vascular Therapy (CIVT) Dr Martin B Leon presented his ‘top picks’ for innovations that will shape the future of TAVR. During his talk, Dr Leon discussed several innovative technologies which could shape the future of how Aortic Stenosis will be treated such as machine learning to better diagnose patients, increased treatments rates, and early intervention. According to Dr Leon TAVR is now firmly established as the standard of care for Aortic Stenosis and will continue its expansion into younger more active patients, underscoring the urgent need for a valve that delivers near-normal hemodynamics and durability. DurAVR™ was the only valve technology mentioned in this presentation.